NEW YORK, Jan 4, 2026, 11:20 ET — Market closed
- Kymera Therapeutics shares ended Friday at $72.76, down 6.5%, for a seventh straight daily decline.
- The stock is down about 13% over the seven-session slide and is nearly 30% below its early-December peak.
- Attention is shifting to 2026 execution: mid-stage trial starts, funding and any new disclosures.
Kymera Therapeutics, Inc. (KYMR) shares closed down 6.5% on Friday at $72.76, extending a losing streak to seven consecutive sessions as the U.S. market heads into the first full trading week of 2026. The stock is down about 13% since Dec. 23 and roughly 29% below the record intraday high of $103 hit in early December. Shares traded between $72.15 and $77.82 on Friday, with about 854,000 shares changing hands. 1
The retreat follows a sharp run-up in early December after Kymera reported positive results from an early-stage patient study of KT-621, its oral anti-inflammatory drug candidate. Chief Executive Nello Mainolfi said the results “exceeded our highest expectations,” while the company said it already had a mid-stage Phase 2b eczema study underway and expected to start a Phase 2b asthma study in the first quarter of 2026. 2
That setup matters now because Kymera’s valuation is still driven by clinical milestones rather than commercial sales, leaving the shares sensitive to shifts in risk appetite and any sign of timeline slippage. After a data-driven spike, investors typically refocus on the harder part: running larger trials, managing cash burn and avoiding unexpected dilution.
Kymera is a clinical-stage biopharmaceutical company developing small-molecule drugs designed to degrade disease-causing proteins, with a primary focus on immunology. The company’s market value is about $4 billion. 3
The broader biotech tape did not offer much cover: the SPDR S&P Biotech ETF (XBI) slipped about 0.3% on Friday, leaving Kymera’s drop standing out.
KT-621 is a “protein degrader,” a type of drug designed to trigger the body’s own disposal machinery to break down a target protein rather than just blocking it. In Kymera’s case, the target is STAT6, a protein involved in immune signaling that can drive inflammatory diseases such as atopic dermatitis and asthma.
Financing remains part of the near-term narrative. Kymera priced an upsized public offering of 7 million shares at $86 per share in December, raising about $602 million in gross proceeds, the company said at the time.
Investors have also watched insider disclosures. A Form 4 filing dated Dec. 31 showed Mainolfi exercised options and sold 30,000 shares, with the sales made under a Rule 10b5-1 plan — a pre-set trading program intended to reduce the appearance of trading on nonpublic information.
From a chart perspective, Friday’s low near $72 marks the first support area traders will watch, with the day’s high near $78 acting as an initial hurdle if the shares rebound. Another sharp break below Friday’s trough would leave the stock probing for a new base after the post-data rally cooled.
But the risks remain familiar for clinical-stage biotech. Early patient results can fade in larger studies, safety findings can emerge with broader exposure, and trial expansion often brings higher costs — which can mean fresh fundraising and added share supply.
